World Pharma News Digest - 05.08.2014
2 views
Skip to first unread message
Ruslan David
Aug 5, 2014, 8:51:51 AM8/5/14
to worldph...@googlegroups.com
Health IT Space Business Social Network (Europe)
You are kindly invited to explore the beta version of the first business social networking platform for Health IT Professionals, named Health IT Space (Europe):
Read more...
http://www.healthitspace.eu
Safety concerns about new drugs revealed
What's safer: a newly approved drug or one that has been on the market much longer? Newer drugs have a one in three chance of acquiring a black box warning or being withdrawn for safety reasons within 25 years of their approval, according to a new study by researchers from Cambridge Health Alliance /Harvard Medical School, Boston Medical Center (BMC)/Boston University School of Medicine (BUSM), City University of New York School of Public Health, and Public Citizen.
Read more...
http://www.worldpharmanews.com/research/2850-safety-concerns-about-new-drugs-revealed
Pepper and halt: Spicy chemical may inhibit gut tumors
Researchers at the University of California, San Diego School of Medicine report that dietary capsaicin - the active ingredient in chili peppers - produces chronic activation of a receptor on cells lining the intestines of mice, triggering a reaction that ultimately reduces the risk of colorectal tumors. The findings are published in the August 1, 2014 issue of The Journal of Clinical Investigation.
Read more...
http://www.worldpharmanews.com/research/2849-pepper-and-halt-spicy-chemical-may-inhibit-gut-tumors
Recent use of some birth control pills may increase breast cancer risk
Women who recently used birth control pills containing high-dose estrogen and a few other formulations had an increased risk for breast cancer, whereas women using some other formulations did not, according to data published in Cancer Research, a journal of the American Association for Cancer Research.
Read more...
http://www.worldpharmanews.com/research/2848-recent-use-of-some-birth-control-pills-may-increase-breast-cancer-risk
Pfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines
Pfizer Inc. has entered into a definitive agreement to acquire Baxter International Inc.'s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter's facility in Orth, Austria, where these vaccines are manufactured.
Read more...
http://www.worldpharmanews.com/pfizer/2847-pfizer-enters-into-agreement-to-acquire-baxters-portfolio-of-marketed-vaccines
AstraZeneca agrees strategic transaction with Almirall in respiratory disease
AstraZeneca today announced that it has entered an agreement to transfer to the company the rights to Almirall's respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments.
Read more...
http://www.worldpharmanews.com/astrazeneca/2846-astrazeneca-agrees-strategic-transaction-with-almirall-in-respiratory-disease-
Bayer continues positive business development
The Bayer Group was again successful in the second quarter of 2014. Sales of the Bayer Group rose by 0.9 percent in the second quarter of 2014 to EUR 10,458 million (Q2 2013: EUR 10,360 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), sales advanced by 6.3 percent.
Read more...
http://www.worldpharmanews.com/bayer/2844-bayer-continues-positive-business-development
Five daily portions of fruit and vegetables may be enough to lower risk of death
These results conflict with a recent study published in BMJ's Journal of Epidemiology and Community Health suggesting that seven or more daily portions of fruits and vegetables were linked to lowest risk of death. There is growing evidence that increasing fruit and vegetable consumption is related to a lower risk of death from cardiovascular disease and cancer.
Read more...
http://www.worldpharmanews.com/research/2845-five-daily-portions-of-fruit-and-vegetables-may-be-enough-to-lower-risk-of-death
Scientists discover new, noncommittal mechanism of drug resistance
Microorganisms like bacteria and fungi can evade treatment by acquiring mutations in the genes targeted by antibiotics or antifungal drugs. These permanent mutations were once thought to be the only way for drug-resistant strains to evolve. Now a new study has shown that microorganisms can use a temporary silencing of drug targets - known as epimutations - to gain the benefits of drug resistance without the commitment.
Read more...
http://www.worldpharmanews.com/research/2843-scientists-discover-new-noncommittal-mechanism-of-drug-resistance
Drugs used to treat lung disease work with the body clock
Scientists from The University of Manchester have discovered why medication to treat asthma and pneumonia can become ineffective. The findings, published in Nature Medicine, show that drugs widely used to treat lung diseases work with the body clock. In the UK pneumonia, which is caused by an infection, affects around 1 in 1000 adults each year and is more serious for babies, young children, the elderly, smokers and those with an underlying health condition.
Read more...
http://www.worldpharmanews.com/research/2842-drugs-used-to-treat-lung-disease-work-with-the-body-clock
Bristol-Myers Squibb reports second quarter 2014 financial results
Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) has reported financial results for the second quarter of 2014, which was highlighted by strong global sales for the company's key brands; the achievement of important regulatory milestones for key brands in Japan, Europe and the U.S.; a new strategic immuno-oncology collaboration agreement with Ono Pharmaceutical Co., Ltd.; and the initiation of several research collaborations that will strengthen the company's leadership position in immuno-oncology.
Read more...
http://www.worldpharmanews.com/bms/2841-bristol-myers-squibb-reports-second-quarter-2014-financial-results
Paracetamol no better than placebo for lower back pain
Paracetamol is no better than placebo at speeding recovery from acute episodes of lower back pain or improving pain levels, function, sleep, or quality of life, according to the first large randomised trial to compare the effectiveness of paracetamol with placebo for low-back pain. The findings, published in The Lancet, question the universal endorsement of paracetamol as the first choice painkiller for low-back pain, say the authors.
Read more...
http://www.worldpharmanews.com/research/2840-paracetamol-no-better-than-placebo-for-lower-back-pain
Rosemary and oregano contain diabetes-fighting compounds
The popular culinary herbs oregano and rosemary are packed with healthful compounds, and now lab tests show they could work in much the same way as prescription anti-diabetic medication, scientists report. In their new study published in ACS' Journal of Agricultural and Food Chemistry, they found that how the herbs are grown makes a difference, and they also identified which compounds contribute the most to this promising trait.
Read more...
http://www.worldpharmanews.com/research/2839-rosemary-and-oregano-contain-diabetes-fighting-compounds
Merck strengthens commitment to Chinese growth market
Merck, a leading company for high-tech products in the pharmaceutical and chemical sectors, today reiterated its commitment to investments in the Chinese market, strengthening a major pillar of its emerging markets growth strategy.
Read more...
http://www.worldpharmanews.com/merckkgaa/2838-merck-strengthens-commitment-to-chinese-growth-market
Transparency lacking in clinical trials
A significant percentage of completed drug clinical trials, especially those funded by industry, are not disclosed to the public, years after being completed - a trend that "threatens the validity of the clinical research literature in the U.S.," according to a study led by a Boston University School of Public Health (BUSPH) researcher.
Read more...
http://www.worldpharmanews.com/research/2837-transparency-lacking-in-clinical-trials
Researchers eliminate the HIV virus from cultured human cells for first time
The HIV-1 virus has proved to be tenacious, inserting its genome permanently into its victims' DNA, forcing patients to take a lifelong drug regimen to control the virus and prevent a fresh attack. Now, a team of Temple University School of Medicine researchers has designed a way to snip out the integrated HIV-1 genes for good.
Read more...
http://www.worldpharmanews.com/research/2836-researchers-eliminate-the-hiv-virus-from-cultured-human-cells-for-first-time
MedImmune and Advaxis partner on immuno-oncology combination clinical trial
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.
Read more...
http://www.worldpharmanews.com/astrazeneca/2835-medimmune-and-advaxis-partner-on-immuno-oncology-combination-clinical-trial
Niacin too dangerous for routine cholesterol therapy
After 50 years of being a mainstay cholesterol therapy, niacin should no longer be prescribed for most patients due to potential increased risk of death, dangerous side effects and no benefit in reducing heart attacks and strokes, writes Northwestern Medicine® preventive cardiologist Donald Lloyd-Jones, M.D., in a New England Journal of Medicine editorial.
Read more...
http://www.worldpharmanews.com/research/2834-niacin-too-dangerous-for-routine-cholesterol-therapy
AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
AstraZeneca today revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre(1).
Read more...
http://www.worldpharmanews.com/astrazeneca/2833-astrazeneca-reveals-designs-for-new-global-rad-centre-and-corporate-headquarters-in-cambridge-uk
Novartis maintained strong innovation momentum in second quarter
Novartis Group net sales increased 2% (+2% cc) to USD 14.6 billion in the second quarter. Growth products contributed USD 4.7 billion or 32% of Group net sales, up 18% (USD) over the prior-year quarter. Group operating income increased 6% (+11% cc) to USD 3.1 billion. Currency had a negative impact of 5 percentage points, primarily due to the stronger Swiss franc and weakening of emerging market currencies, partly offset by a stronger euro.
Read more...
http://www.worldpharmanews.com/novartis/2832-novartis-maintained-strong-innovation-momentum-in-second-quarter
Pfizer to Acquire InnoPharma, Inc.
Pfizer Inc. (NYSE:PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma.
Read more...
http://www.worldpharmanews.com/pfizer/2831-pfizer-to-acquire-innopharma-inc
PharmaNews.eu / Latest News
Potential basis for the treatment and prevention of Parkinson's disease
http://www.pharmanews.eu/research-and-development/1465-potential-basis-for-the-treatment-and-prevention-of-parkinsons-disease
Is Europe putting cancer research at risk?
http://www.pharmanews.eu/research-and-development/1464-is-europe-putting-cancer-research-at-risk
European Telemedicine Conference 2014
http://www.pharmanews.eu/conferences-and-events/1463-european-telemedicine-conference-2014
Medical Entrepreneur Start-up Hospital - M.E.S.H Camp 2014
http://www.pharmanews.eu/conferences-and-events/1462-medical-entrepreneur-start-up-hospital-mesh-camp-2014
Scientists map one of most important proteins in life - and cancer
http://www.pharmanews.eu/research-and-development/1461-scientists-map-one-of-most-important-proteins-in-life-and-cancer
Taking B vitamins won't prevent Alzheimer's disease
http://www.pharmanews.eu/research-and-development/1458-taking-b-vitamins-wont-prevent-alzheimers-disease
New research reveals how cannabis compound could slow tumour growth
http://www.pharmanews.eu/research-and-development/1460-new-research-reveals-how-cannabis-compound-could-slow-tumour-growth
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
Health IT Space, http://www.healthitspace.eu
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
You are kindly invited to explore the beta version of the first business social networking platform for Health IT Professionals, named Health IT Space (Europe):
Read more...
http://www.healthitspace.eu
Safety concerns about new drugs revealed
What's safer: a newly approved drug or one that has been on the market much longer? Newer drugs have a one in three chance of acquiring a black box warning or being withdrawn for safety reasons within 25 years of their approval, according to a new study by researchers from Cambridge Health Alliance /Harvard Medical School, Boston Medical Center (BMC)/Boston University School of Medicine (BUSM), City University of New York School of Public Health, and Public Citizen.
Read more...
http://www.worldpharmanews.com/research/2850-safety-concerns-about-new-drugs-revealed
Pepper and halt: Spicy chemical may inhibit gut tumors
Researchers at the University of California, San Diego School of Medicine report that dietary capsaicin - the active ingredient in chili peppers - produces chronic activation of a receptor on cells lining the intestines of mice, triggering a reaction that ultimately reduces the risk of colorectal tumors. The findings are published in the August 1, 2014 issue of The Journal of Clinical Investigation.
Read more...
http://www.worldpharmanews.com/research/2849-pepper-and-halt-spicy-chemical-may-inhibit-gut-tumors
Recent use of some birth control pills may increase breast cancer risk
Women who recently used birth control pills containing high-dose estrogen and a few other formulations had an increased risk for breast cancer, whereas women using some other formulations did not, according to data published in Cancer Research, a journal of the American Association for Cancer Research.
Read more...
http://www.worldpharmanews.com/research/2848-recent-use-of-some-birth-control-pills-may-increase-breast-cancer-risk
Pfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines
Pfizer Inc. has entered into a definitive agreement to acquire Baxter International Inc.'s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter's facility in Orth, Austria, where these vaccines are manufactured.
Read more...
http://www.worldpharmanews.com/pfizer/2847-pfizer-enters-into-agreement-to-acquire-baxters-portfolio-of-marketed-vaccines
AstraZeneca agrees strategic transaction with Almirall in respiratory disease
AstraZeneca today announced that it has entered an agreement to transfer to the company the rights to Almirall's respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments.
Read more...
http://www.worldpharmanews.com/astrazeneca/2846-astrazeneca-agrees-strategic-transaction-with-almirall-in-respiratory-disease-
Bayer continues positive business development
The Bayer Group was again successful in the second quarter of 2014. Sales of the Bayer Group rose by 0.9 percent in the second quarter of 2014 to EUR 10,458 million (Q2 2013: EUR 10,360 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), sales advanced by 6.3 percent.
Read more...
http://www.worldpharmanews.com/bayer/2844-bayer-continues-positive-business-development
Five daily portions of fruit and vegetables may be enough to lower risk of death
These results conflict with a recent study published in BMJ's Journal of Epidemiology and Community Health suggesting that seven or more daily portions of fruits and vegetables were linked to lowest risk of death. There is growing evidence that increasing fruit and vegetable consumption is related to a lower risk of death from cardiovascular disease and cancer.
Read more...
http://www.worldpharmanews.com/research/2845-five-daily-portions-of-fruit-and-vegetables-may-be-enough-to-lower-risk-of-death
Scientists discover new, noncommittal mechanism of drug resistance
Microorganisms like bacteria and fungi can evade treatment by acquiring mutations in the genes targeted by antibiotics or antifungal drugs. These permanent mutations were once thought to be the only way for drug-resistant strains to evolve. Now a new study has shown that microorganisms can use a temporary silencing of drug targets - known as epimutations - to gain the benefits of drug resistance without the commitment.
Read more...
http://www.worldpharmanews.com/research/2843-scientists-discover-new-noncommittal-mechanism-of-drug-resistance
Drugs used to treat lung disease work with the body clock
Scientists from The University of Manchester have discovered why medication to treat asthma and pneumonia can become ineffective. The findings, published in Nature Medicine, show that drugs widely used to treat lung diseases work with the body clock. In the UK pneumonia, which is caused by an infection, affects around 1 in 1000 adults each year and is more serious for babies, young children, the elderly, smokers and those with an underlying health condition.
Read more...
http://www.worldpharmanews.com/research/2842-drugs-used-to-treat-lung-disease-work-with-the-body-clock
Bristol-Myers Squibb reports second quarter 2014 financial results
Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) has reported financial results for the second quarter of 2014, which was highlighted by strong global sales for the company's key brands; the achievement of important regulatory milestones for key brands in Japan, Europe and the U.S.; a new strategic immuno-oncology collaboration agreement with Ono Pharmaceutical Co., Ltd.; and the initiation of several research collaborations that will strengthen the company's leadership position in immuno-oncology.
Read more...
http://www.worldpharmanews.com/bms/2841-bristol-myers-squibb-reports-second-quarter-2014-financial-results
Paracetamol no better than placebo for lower back pain
Paracetamol is no better than placebo at speeding recovery from acute episodes of lower back pain or improving pain levels, function, sleep, or quality of life, according to the first large randomised trial to compare the effectiveness of paracetamol with placebo for low-back pain. The findings, published in The Lancet, question the universal endorsement of paracetamol as the first choice painkiller for low-back pain, say the authors.
Read more...
http://www.worldpharmanews.com/research/2840-paracetamol-no-better-than-placebo-for-lower-back-pain
Rosemary and oregano contain diabetes-fighting compounds
The popular culinary herbs oregano and rosemary are packed with healthful compounds, and now lab tests show they could work in much the same way as prescription anti-diabetic medication, scientists report. In their new study published in ACS' Journal of Agricultural and Food Chemistry, they found that how the herbs are grown makes a difference, and they also identified which compounds contribute the most to this promising trait.
Read more...
http://www.worldpharmanews.com/research/2839-rosemary-and-oregano-contain-diabetes-fighting-compounds
Merck strengthens commitment to Chinese growth market
Merck, a leading company for high-tech products in the pharmaceutical and chemical sectors, today reiterated its commitment to investments in the Chinese market, strengthening a major pillar of its emerging markets growth strategy.
Read more...
http://www.worldpharmanews.com/merckkgaa/2838-merck-strengthens-commitment-to-chinese-growth-market
Transparency lacking in clinical trials
A significant percentage of completed drug clinical trials, especially those funded by industry, are not disclosed to the public, years after being completed - a trend that "threatens the validity of the clinical research literature in the U.S.," according to a study led by a Boston University School of Public Health (BUSPH) researcher.
Read more...
http://www.worldpharmanews.com/research/2837-transparency-lacking-in-clinical-trials
Researchers eliminate the HIV virus from cultured human cells for first time
The HIV-1 virus has proved to be tenacious, inserting its genome permanently into its victims' DNA, forcing patients to take a lifelong drug regimen to control the virus and prevent a fresh attack. Now, a team of Temple University School of Medicine researchers has designed a way to snip out the integrated HIV-1 genes for good.
Read more...
http://www.worldpharmanews.com/research/2836-researchers-eliminate-the-hiv-virus-from-cultured-human-cells-for-first-time
MedImmune and Advaxis partner on immuno-oncology combination clinical trial
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.
Read more...
http://www.worldpharmanews.com/astrazeneca/2835-medimmune-and-advaxis-partner-on-immuno-oncology-combination-clinical-trial
Niacin too dangerous for routine cholesterol therapy
After 50 years of being a mainstay cholesterol therapy, niacin should no longer be prescribed for most patients due to potential increased risk of death, dangerous side effects and no benefit in reducing heart attacks and strokes, writes Northwestern Medicine® preventive cardiologist Donald Lloyd-Jones, M.D., in a New England Journal of Medicine editorial.
Read more...
http://www.worldpharmanews.com/research/2834-niacin-too-dangerous-for-routine-cholesterol-therapy
AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
AstraZeneca today revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre(1).
Read more...
http://www.worldpharmanews.com/astrazeneca/2833-astrazeneca-reveals-designs-for-new-global-rad-centre-and-corporate-headquarters-in-cambridge-uk
Novartis maintained strong innovation momentum in second quarter
Novartis Group net sales increased 2% (+2% cc) to USD 14.6 billion in the second quarter. Growth products contributed USD 4.7 billion or 32% of Group net sales, up 18% (USD) over the prior-year quarter. Group operating income increased 6% (+11% cc) to USD 3.1 billion. Currency had a negative impact of 5 percentage points, primarily due to the stronger Swiss franc and weakening of emerging market currencies, partly offset by a stronger euro.
Read more...
http://www.worldpharmanews.com/novartis/2832-novartis-maintained-strong-innovation-momentum-in-second-quarter
Pfizer to Acquire InnoPharma, Inc.
Pfizer Inc. (NYSE:PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma.
Read more...
http://www.worldpharmanews.com/pfizer/2831-pfizer-to-acquire-innopharma-inc
PharmaNews.eu / Latest News
Potential basis for the treatment and prevention of Parkinson's disease
http://www.pharmanews.eu/research-and-development/1465-potential-basis-for-the-treatment-and-prevention-of-parkinsons-disease
Is Europe putting cancer research at risk?
http://www.pharmanews.eu/research-and-development/1464-is-europe-putting-cancer-research-at-risk
European Telemedicine Conference 2014
http://www.pharmanews.eu/conferences-and-events/1463-european-telemedicine-conference-2014
Medical Entrepreneur Start-up Hospital - M.E.S.H Camp 2014
http://www.pharmanews.eu/conferences-and-events/1462-medical-entrepreneur-start-up-hospital-mesh-camp-2014
Scientists map one of most important proteins in life - and cancer
http://www.pharmanews.eu/research-and-development/1461-scientists-map-one-of-most-important-proteins-in-life-and-cancer
Taking B vitamins won't prevent Alzheimer's disease
http://www.pharmanews.eu/research-and-development/1458-taking-b-vitamins-wont-prevent-alzheimers-disease
New research reveals how cannabis compound could slow tumour growth
http://www.pharmanews.eu/research-and-development/1460-new-research-reveals-how-cannabis-compound-could-slow-tumour-growth
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
Health IT Space, http://www.healthitspace.eu
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages